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Abstract
Introduction:
Probiotics have been promoted for use in many gastrointestinal ailments. Most studies find
probiotics safe for human use, reporting no severe adverse effects. However, probiotics are
live microorganisms and thus have the potential to cause infection. Transplant recipients are
considered at high risk for infectious complications from probiotics due to the
immunosuppressive medications used to prevent organ rejection. Nonetheless, clinicians are
currently utilizing probiotics in the transplant population, due to their benefit in
gastrointestinal disorders, particularly recurrent Clostridium difficile. Limited knowledge and
paucity of prospective trials in this patient population demands the need for completion of
studies to identify the safety of probiotics in transplant patients.
Objective:
The primary objective of this study was to investigate the safety of utilizing Saccharomyces
boulardii for the prevention of antibiotic-associated diarrhea in kidney, pancreas, and liver
transplant recipients. A secondary objective of this study was to evaluate the efficacy of the
use of Saccharomyces boulardii to prevent antibiotic-associated diarrhea.
Methods:
A prospective chart review was performed to assess the safety of Saccharomyces boulardii in
transplant patients. All kidney, pancreas, and liver transplant patients who received
Saccharomyces boulardii were included in the safety analysis. Only those who meet criteria
for the prevention of antibiotic-associated diarrhea with Saccharomyces boulardii were
included in the efficacy analysis.
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Results:
No infections due to the probiotic, Saccharomyces boulardii, in 16 solid organ transplant
patients treated were observed.
Conclusion:
There are multiple of case reports regarding infectious complications of probiotics,
particularly in groups at high risk for infection. However, some studies have shown
probiotics given immediately after transplantation may help restore normal gut flora and
prevent the translocation of bacteria across the gut wall thereby preventing infections in these
immunosuppressed patients. This study found no infectious complications of probiotics in
solid organ transplant recipients.
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Introduction:
The World Health Organization and the Food and Agriculture Organization of the
United Nations define probiotics as "live microorganisms which when administered in
adequate amounts confer a heath benefit to the host."1 In recent years, probiotics have been
promoted for use in many disease states. In the hospital setting, probiotics are mainly used to
replenish the colon microflora in patients with diarrhea due to antibiotics or to prevent
recurrence of disease following treatment of Clostridium difficile colitis.2
Most studies have found probiotics safe for human use, reporting no severe adverse
effects. However, probiotics are live microorganisms and have the potential to cause
infection. Patients at a higher risk of developing infection from probiotic therapy include
those with immunosuppressed states, critical or terminal illness, prosthetic heart valves,
bowel surgery, history of rheumatic heart disease or infective endocarditis, or use of proton
pump inhibitors or histamine H2 antagonists. These higher risk patients are often excluded
from probiotic studies limiting knowledge concerning the safety of probiotic therapy in these
populations.Y'r'
Organ transplant recipients are considered a high risk group for infectious
complications from probiotic therapy due to the administration of immunosuppressive
medications used to prevent organ rejection." Conversely, some studies have shown
probiotics beneficial in restoring normal gut flora and preventing the translocation of bacteria
across the gut wall and thereby preventing infections in these immunosuppressed patients. 7,8
There are no previous prospective trials regarding the use of a Saccharomyces
probiotic in the solid organ transplant population. The primary objective of this study was to
investigate the safety of using Saccharomyces boulardii for the prevention of antibiotic-
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associated diarrhea in solid organ transplant recipients. A secondary objective of this study
was to evaluate the efficacy of the use of Saccharomyces boulardii to prevent antibiotic-
associated diarrhea.
Methods
All patients> 18 years of age who were recipients of a simultaneous kidney/pancreas,
pancreas after kidney, isolated pancreas or liver transplant and were initiated on
Saccharomyces boulardii therapy while admitted to the organ transplant unit at Indiana
University Hospital from July 1,2011 to March 1,2012 were eligible for this prospective
study. Patients who were pregnant, had a known hypersensitivity to Saccharomyces spp., or
received other probiotics prior to admission were excluded. Following approval from the
Indiana University School of Medicine Institutional Review Board, data was collected from
the electronic medical record including age, sex, admission diagnosis, medical history,
concomitant illness, documented infection via culture results, probiotic administration
information, and results of tests for Clostridium difficile. Clinical outcomes data was also
collected which included incidence of diarrhea or constipation, infectious complications, and
other serious adverse effects associated with the probiotic therapy. Data was assessed using
descriptive statistics. All patients were included in the safety analysis to determine the
incidence of infectious complications due to Saccharomyces boulardii. Those patients who
received antibiotic therapy as well as Saccharomyces boulardii and no other probiotic were
included in the efficacy analysis to determine the benefit of Saccharomyces boulardii for the
prevention of antibiotic associated diarrhea.
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Results:
Sixteen patients received probiotics with no documented infections or other serious
complications. The demographics of the patient population are shown in Table 1. Five of
these patients met the criteria for efficacy analysis of prevention of antibiotic-associated
diarrhea with Saccharomyces boulardii. Three of these patients experienced diarrhea. Two
had been admitted with diarrhea and found to have Clostridiums difficile colitis and were
treated with either the standard of care for Clostridium difficile colitis (metronidazole or
vancomycin) in addition to the Saccharomyces boulardii. Both patients had resolution of
their diarrhea with this treatment. The other patient experienced diarrhea after 5 days of
probiotic therapy. The probiotic was continued and due to improvement of diarrhea the
patient was discharged on the probiotic.
Discussion:
In this study, Saccharomyces boulardii therapy was well tolerated in pancreas,
kidney, and liver transplant patients with no serious adverse effects. Although this was a
small study, it contradicts literature showing infectious complications of probiotics
particularly in patients who are immunosuppressed. Current guidelines for the prevention and
treatment of Clostridium difficile infection from the Society for Healthcare Epidemiology of
America and the Infectious Diseases Society of America state "administration of currently
available probiotics is not recommended to prevent primary Clostridium difficile infection, as
there are limited data to support this approach and there is a potential risk of bloodstream
infection.,,9 These guidelines also discourage the use of Saccharomyces spp. therapy;
"administration of Saccharomyces boulardii has, however, been associated with fungemia in
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immunocompromised patients and in patients with central venous lines, and should be
avoided in critically ill patients.?"
These recommendations are based on case reports that describe infectious
complications of probiotics in groups at risk for infection. Ina review of 92 cases of invasive
infections due to Saccharomyces spp., Saccharomyces boulardii was responsible for 37
fungemias.i" Of these patients, 32 had taken a probiotic that contained Saccharomyces
boulardii. Those who had a Saccharomyces boulardii infection were more likely to have a
digestive tract disease, a central venous catheter, and be hospitalized in an intensive care
unit. 10
Munoz, and colleagues, II investigated an outbreak of Saccharomyces cerevisiae
fungemias in an intensive care unit. The investigators revealed the commonality between the
three patients with fungemia was treatment with a Saccharomyces boulardii probiotic, brand
name Ultralevura®. Both the probiotic strain of yeast and the blood cultures isolated from the
three patients were identified by the hospital microbiology laboratory as Saccharomyces
cerevisiae with identical DNA fingerprinting. Discontinuation of the probiotic product ended
further infections in the unit. II
Like critically ill patients, organ transplant recipients are considered high risk for
infectious complications of probiotics. The purported reason suggested for this increased risk
of infectious complications in transplant recipients is the immune compromised state induced
from the transplant medications required to prevent rejection of the transplanted organ."
Luong and colleagues 12 report their experience in which a 56-year-old male with
human immunodeficiency virus underwent a double-lung transplant and developed an
empyema which cultured positive for Lactobacillus rhamnosus GG, the strain of bacteria
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identical to the probiotic administered as part of the standard post-transplant Clostridium
difficile prophylaxis regime. 12 Riquelme and colleagues'< report a case ofa 42-year-old
woman, having received a kidney-pancreas transplant developed Saccharomyces cerevisiae
fungemia after treatment with Saccharomyces boulardii for Clostridium difficile. Though the
strain of Saccharomyces spp. was S. cerevisiae and not S. boulardii, the investigators
concluded the fungemia was a result of the administration of the probiotic as it is very
difficult for most laboratories to distinguish Saccharomyces boulardii from Saccharomyces
., 13cerevtsiae.
In our study, conclusions regarding efficacy cannot be made due to the limited
number of patients meeting the inclusion criteria at this time. Trials have shown benefit with
the use of probiotics for diarrhea. In a study conducted by Hickson and colleagues.!" 135
older adults taking antibiotics were randomized to receive either a probiotic drink containing
Lactobacillus casei, Lactobacillus bulgaricus, and Streptococcus thermophilus or a sterile
milkshake. The incidence of both antibiotic-associated and Clostridium difficile diarrhea was
decreased in the probiotic group.
In a review of probiotics by Imhoff and Karpa, 15 a tendency towards benefits from
probiotics was observed. Clinical trials of probiotics containing multiple strains were shown
to be most favorable for primary prevention of Clostridium difjicile associated disease.
However, clinical trials and case reports of the probiotic Saccharomyces boulardii in
combination with high-dose vancomycin were most advantageous for the prevention of
di 2,15recurrence isease.
Current guidelines for the use of nutritional support in critical ill patients from the
Society of Critical Care Medicine and the American Society for Parenteral and Enteral
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Nutrition state, "administration of probiotic agents has been shown to improve outcome
(most consistently by decreasing infection) in specific critically ill patient populations
involving transplantation, major abdominal surgery, and severe trauma.v'" However, the
guidelines do not recommend one probiotic strain or combination over another. "It seems that
each species may have different effects and variable impact on patient outcome, making it
difficult to make broad categorical recommendations." 16
Rayes and colleagues 7,8 have shown the administration of probiotics immediately
after transplantation may help restore normal gut flora and prevent translocation of bacteria
across the gut wall thus preventing infections in these immunosuppressed patients. In a group
of 66 adult liver transplant patients, those patients treated with a probiotic containing
Pediacoccus pentosaceus, Leuconostoc mesenteroides, Lactobacillus paracasei, and
Lactobacillus plantarum twice daily for 14 days immediately post-transplantation showed a
significant decrease in post-operative infections. Post-operative infections were seen in 48%
of patients who did not receive probiotic therapy and 3% of patients who received probiotic
therapy.'
Conclusion:
Although the use ofprobiotics in solid organ transplant recipients and other
immunocompromised individuals is controversial, they are still utilized in these populations.
This prospective trial found no infectious complications with the administration of the
probiotic Saccharomyces boulardii in sixteen solid organ transplant patients. Further research
is required to determine the safety of probiotics, including Saccharomyces boulardii, in the
solid organ transplant population.
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